Journal of Cardiovascular Translational Research

, Volume 6, Issue 1, pp 31–36

Modeling Long-QT Syndromes with iPS Cells

Authors

    • I. Medizinische Klinik Kardiologie, Klinikum rechts der IsarTechnische Universität München
  • Alexander Goedel
    • I. Medizinische Klinik Kardiologie, Klinikum rechts der IsarTechnische Universität München
  • Tatjana Dorn
    • I. Medizinische Klinik Kardiologie, Klinikum rechts der IsarTechnische Universität München
  • Ralf J. Dirschinger
    • I. Medizinische Klinik Kardiologie, Klinikum rechts der IsarTechnische Universität München
  • Alessandra Moretti
    • I. Medizinische Klinik Kardiologie, Klinikum rechts der IsarTechnische Universität München
  • Karl-Ludwig Laugwitz
    • I. Medizinische Klinik Kardiologie, Klinikum rechts der IsarTechnische Universität München
Article

DOI: 10.1007/s12265-012-9416-1

Cite this article as:
Sinnecker, D., Goedel, A., Dorn, T. et al. J. of Cardiovasc. Trans. Res. (2013) 6: 31. doi:10.1007/s12265-012-9416-1

Abstract

The generation of induced pluripotent stem cells (iPSC) from human somatic cells bears the possibility to generate patient-specific stem cell lines which can serve as a theoretically unlimited source of somatic cells carrying the genotype of the patients. Different types of the long-QT syndrome have been studied by analyzing the phenotype of cardiomyocytes generated from patient-specific iPSC lines. Major aspects of the pathophysiology of long-QT syndrome, like prolonged action potentials, arrhythmia, and the effects of pro- and antiarrhythmic drugs could be recapitulated in these cells. In the future, patient-specific iPSC-derived cardiomyocytes might be used to screen for new drugs, to avoid unwanted drug side effects, and to deepen our understanding on the pathophysiology of long-QT syndromes.

Keywords

LQTLong-QT syndromeDisease modelingiPS cellsReprogramming

Copyright information

© Springer Science+Business Media New York 2012